{"doi":"10.1089\/ars.2007.1769","coreId":"196304","oai":"oai:lra.le.ac.uk:2381\/8477","identifiers":["oai:lra.le.ac.uk:2381\/8477","10.1089\/ars.2007.1769"],"title":"Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials","authors":["Strimpakos, Alexios S.","Sharma, Ricky A."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2008-01-16","abstract":"Full text of this article is not available on the LRA. The published version can be found at: http:\/\/www.liebertonline.com\/ars\\ud\ndoi:10.1089\/ars.2007.1769Curcumin is a natural polyphenol used in ancient Asian medicine. Since the first article referring to the use\\ud\nof curcumin to treat human disease was published in The Lancet in 1937,  2,600 research studies using curcumin\\ud\nor turmeric have been published in English language journals. The mechanisms implicated in the inhibition\\ud\nof tumorigenesis by curcumin are diverse and appear to involve a combination of antiinflammatory,\\ud\nantioxidant, immunomodulatory, proapoptotic, and antiangiogenic properties via pleiotropic effects on genes\\ud\nand cell-signaling pathways at multiple levels. The potentially adverse sequelae of curcumin\u2019s effects on\\ud\nproapoptotic genes, particularly p53, represent a cause for current debate. When curcumin is combined with\\ud\nsome cytotoxic drugs or certain other diet-derived polyphenols, synergistic effects have been demonstrated.\\ud\nAlthough curcumin\u2019s low systemic bioavailability after oral dosing may limit access of sufficient concentrations\\ud\nfor pharmacologic effects in tissues outside the gastrointestinal tract, chemical analogues and novel delivery\\ud\nmethods are in preclinical development to overcome this barrier. This article provides an overview of\\ud\nthe extensive published literature on the use of curcumin as a therapy for malignant and inflammatory diseases\\ud\nand its potential use in the treatment of degenerative neurologic diseases, cystic fibrosis, and cardiovascular\\ud\ndiseases. Despite the breadth of the coverage, particular emphasis is placed on the prevention and\\ud\ntreatment of human cancers","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Mary Ann Liebert, Inc. publishers","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:lra.le.ac.uk:2381\/8477<\/identifier><datestamp>\n                2010-09-13T10:57:20Z<\/datestamp><setSpec>\n                com_2381_162<\/setSpec><setSpec>\n                com_2381_9550<\/setSpec><setSpec>\n                col_2381_163<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nCurcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials<\/dc:title><dc:creator>\nStrimpakos, Alexios S.<\/dc:creator><dc:creator>\nSharma, Ricky A.<\/dc:creator><dc:description>\nFull text of this article is not available on the LRA. The published version can be found at: http:\/\/www.liebertonline.com\/ars\\ud\ndoi:10.1089\/ars.2007.1769<\/dc:description><dc:description>\nCurcumin is a natural polyphenol used in ancient Asian medicine. Since the first article referring to the use\\ud\nof curcumin to treat human disease was published in The Lancet in 1937,  2,600 research studies using curcumin\\ud\nor turmeric have been published in English language journals. The mechanisms implicated in the inhibition\\ud\nof tumorigenesis by curcumin are diverse and appear to involve a combination of antiinflammatory,\\ud\nantioxidant, immunomodulatory, proapoptotic, and antiangiogenic properties via pleiotropic effects on genes\\ud\nand cell-signaling pathways at multiple levels. The potentially adverse sequelae of curcumin\u2019s effects on\\ud\nproapoptotic genes, particularly p53, represent a cause for current debate. When curcumin is combined with\\ud\nsome cytotoxic drugs or certain other diet-derived polyphenols, synergistic effects have been demonstrated.\\ud\nAlthough curcumin\u2019s low systemic bioavailability after oral dosing may limit access of sufficient concentrations\\ud\nfor pharmacologic effects in tissues outside the gastrointestinal tract, chemical analogues and novel delivery\\ud\nmethods are in preclinical development to overcome this barrier. This article provides an overview of\\ud\nthe extensive published literature on the use of curcumin as a therapy for malignant and inflammatory diseases\\ud\nand its potential use in the treatment of degenerative neurologic diseases, cystic fibrosis, and cardiovascular\\ud\ndiseases. Despite the breadth of the coverage, particular emphasis is placed on the prevention and\\ud\ntreatment of human cancers.<\/dc:description><dc:date>\n2010-09-13T09:44:30Z<\/dc:date><dc:date>\n2010-09-13T09:44:30Z<\/dc:date><dc:date>\n2008-01-16<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nAntioxidants and Redox Signaling, 2008,10(3),pp.511-45.<\/dc:identifier><dc:identifier>\n1523-0864<\/dc:identifier><dc:identifier>\nhttp:\/\/dx.doi.org\/10.1089\/ars.2007.1769<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/2381\/8477<\/dc:identifier><dc:language>\nen<\/dc:language><dc:format>\nMetadata only<\/dc:format><dc:publisher>\nMary Ann Liebert, Inc. publishers<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":[{"title":null,"identifiers":["issn:1523-0864","1523-0864"]}],"language":null,"relations":[],"year":2008,"topics":[],"subject":["Article"],"fullText":null}